Stefan Schreiber, ECCO 2021: Risankizumab – an Induction Therapy for Crohn’s Disease
We were delighted to catch up with Professor Stefan Schreiber (University Hospital Schleswig-Holstein, Kiel, Germany) to discuss the results from the phase 3 ADVANCE and MOTIVATE studies, investigating risankizumab as an induction therapy in patients with moderate-to-severe Crohn’s Disease. The abstract ‘Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn’s Disease: Results […]
Stefan Schreiber, ECCO 2021: Filgotinib for the Treatment of Ulcerative Colitis
TouchIMMUNOLOGY had the pleasure of talking to Professor Stefan Schreiber (University Hospital Schleswig-Holstein, Kiel, Germany) around the efficacy and safety findings from the SELECTION study and its long term extension. The abstract ‘Safety analysis of filgotinib for Ulcerative Colitis: Results from the phase 2b/3 SELECTION study and phase 3 SELECTIONLTE long-term extension study.‘ (OP04) was […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!